Recent PRLD News
- Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting • GlobeNewswire Inc. • 04/09/2024 08:35:00 PM
- Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual Meeting • GlobeNewswire Inc. • 03/05/2024 09:45:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2024 11:07:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2024 11:07:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2024 11:05:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2024 11:01:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2024 10:59:05 PM
- Prelude Therapeutics to Participate in Barclays Global Healthcare Conference • GlobeNewswire Inc. • 02/29/2024 09:05:08 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/15/2024 10:22:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/15/2024 09:22:04 PM
- Prelude Therapeutics Reports Full Year 2023 Financial Results and Outlines Key Objectives for 2024 • GlobeNewswire Inc. • 02/15/2024 09:05:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/12/2024 09:26:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/08/2024 10:00:40 PM
- Prelude Therapeutics Announces $25 Million Private Placement • GlobeNewswire Inc. • 12/11/2023 02:34:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/11/2023 02:17:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/01/2023 08:37:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/01/2023 08:23:56 PM
- Prelude Announces Strategic Pipeline Progress and Updates, including its Partnership with AbCellera, and Reports Third Quarter Financial Results • GlobeNewswire Inc. • 11/01/2023 08:10:00 PM
- Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology • Business Wire • 11/01/2023 08:05:00 PM
- Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology • GlobeNewswire Inc. • 11/01/2023 08:05:00 PM
- Prelude Announces Multiple Clinical and Preclinical Poster Presentations at AACR-NCI-EORTC International Conference • GlobeNewswire Inc. • 10/14/2023 04:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/06/2023 01:07:55 PM
- Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in September • GlobeNewswire Inc. • 08/29/2023 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/03/2023 12:14:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/03/2023 12:10:58 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM